Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe

[1]  R. Deb,et al.  Multidisciplinary team approach in breast cancer care: Benefits and challenges , 2020, Indian journal of pathology & microbiology.

[2]  P. Fasching,et al.  International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts , 2020, Breast Care.

[3]  O. Razum,et al.  The role of acculturation in migrants’ use of gynecologic emergency departments , 2020, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[4]  E. Finkelstein,et al.  A feasible and acceptable multicultural psychosocial intervention targeting symptom management in the context of advanced breast cancer , 2019, Psycho-oncology.

[5]  E. Basch,et al.  Using Stakeholder Engagement to Overcome Barriers to Implementing Patient-reported Outcomes (PROs) in Cancer Care Delivery: Approaches From 3 Prospective Studies. , 2019, Medical care.

[6]  C. White,et al.  Inequalities in health? An update on the effect of social deprivation for patients with breast cancer in South East Wales. , 2019, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[7]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[8]  Paul B Tchounwou,et al.  Health and Racial Disparity in Breast Cancer. , 2019, Advances in experimental medicine and biology.

[9]  M. Lux,et al.  Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry , 2018, Cancers.

[10]  Xin Hu,et al.  Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics , 2018, Breast Cancer Research and Treatment.

[11]  F. Cardoso,et al.  Global analysis of metastatic breast cancer policy gaps and advocacy efforts across the patient journey. , 2018, Breast.

[12]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[13]  S. Hurvitz,et al.  Advances in the use of PARP inhibitor therapy for breast cancer , 2018, Drugs in context.

[14]  N S El Saghir,et al.  4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  B. Hennessy,et al.  Barriers to care for breast cancer: A qualitative study in Ireland , 2018, European journal of cancer care.

[16]  F. Cardoso,et al.  Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015). , 2018, Breast.

[17]  Krista A. Zanetti,et al.  Social factors matter in cancer risk and survivorship , 2018, Cancer Causes & Control.

[18]  F. Puglisi,et al.  Atezolizumab for the treatment of breast cancer , 2018, Expert opinion on biological therapy.

[19]  S. Mathoulin-Pélissier,et al.  Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. , 2018, European journal of cancer.

[20]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[21]  M. Lux,et al.  Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. , 2018, Breast.

[22]  J. McElroy,et al.  Unmet support needs of sexual and gender minority breast cancer survivors , 2018, Supportive Care in Cancer.

[23]  D. Hendrie,et al.  Understanding the effects of socioeconomic status along the breast cancer continuum in Australian women: a systematic review of evidence , 2017, International Journal for Equity in Health.

[24]  R. Epstein,et al.  Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Tesch,et al.  Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer - Results from the prospective German TMK cohort study. , 2017, Breast.

[26]  R. Jagsi,et al.  Patient Preferences for Primary Care Provider Roles in Breast Cancer Survivorship Care. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Flowers,et al.  Obstacles, Opportunities and Priorities for Advancing Metastatic Breast Cancer Research. , 2017, Cancer research.

[28]  B. Anderson,et al.  Breast Cancer Disparities at Home and Abroad: A Review of the Challenges and Opportunities for System-Level Change , 2017, Clinical Cancer Research.

[29]  P. Giorgi Rossi,et al.  [Cervical and breast cancer screening among immigrant women resident in Italy]. , 2017, Epidemiologia e prevenzione.

[30]  J. Borrás,et al.  Psychosocial oncology care resources in Europe: a study under the European Partnership for Action Against Cancer (EPAAC) , 2017, Psycho-oncology.

[31]  Richard Sullivan,et al.  The global burden of women’s cancers: a grand challenge in global health , 2017, The Lancet.

[32]  L. Brudin,et al.  Improved survival in metastatic breast cancer 1985-2016. , 2017, Breast.

[33]  N. Dabelić,et al.  Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors. , 2017, Breast.

[34]  B. Rechel,et al.  Utilization of health care services by migrants in Europe—a systematic literature review , 2017, British medical bulletin.

[35]  Giuseppe La Torre,et al.  European Guide on Quality Improvement in Comprehensive Cancer Control , 2017 .

[36]  L. Pezzin,et al.  Socioeconomic status and breast cancer treatment , 2017, Breast Cancer Research and Treatment.

[37]  J. Bergh,et al.  The European Cancer Patient’s Bill of Rights, update and implementation 2016 , 2016, ESMO Open.

[38]  B. Sikic,et al.  Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. , 2016, The oncologist.

[39]  Lesley Fallowfield,et al.  Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Ana-Maria Forsea,et al.  Cancer registries in Europe—going forward is the only option , 2016, Ecancermedicalscience.

[41]  P. Fernández-Ortega,et al.  Left behind: cancer disparities in the developed world , 2016, Supportive Care in Cancer.

[42]  R. Sullivan,et al.  Health policy: Putting a price on cancer , 2016, Nature Reviews Clinical Oncology.

[43]  J. Ahn,et al.  The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC) , 2016, PloS one.

[44]  Michael Corr.  So you want to be an Erasmus Medical Student? , 2016, The Ulster medical journal.

[45]  Michael Baumann,et al.  Expanding global access to radiotherapy. , 2015, The Lancet. Oncology.

[46]  D. Sharp,et al.  Clinical features of metastatic cancer in primary care: a case-control study using medical records. , 2015, The British journal of general practice : the journal of the Royal College of General Practitioners.

[47]  M. Piccart,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  Karla Unger-Saldaña,et al.  Challenges to the early diagnosis and treatment of breast cancer in developing countries. , 2014, World journal of clinical oncology.

[49]  P. Neven,et al.  Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer , 2014, Current medical research and opinion.

[50]  J. Bergh,et al.  A catalyst for change: the European cancer Patient's Bill of Rights. , 2014, The oncologist.

[51]  L. V. van't Veer,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). , 2014, Breast.

[52]  Eld,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) , 2014, Breast.

[53]  L. Carey,et al.  Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. , 2013, The oncologist.

[54]  R. Bechhold.  “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines” , 2013 .

[55]  Suzanne M. Miller,et al.  Adult Cancer Survivors Discuss Follow-up in Primary Care: ‘Not What I Want, But Maybe What I Need’ , 2012, The Annals of Family Medicine.

[56]  D. Fenlon,et al.  Training breast care nurses throughout Europe: the EONS postbasic curriculum for breast cancer nursing. , 2012, European journal of cancer.

[57]  David S Morrison,et al.  Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women , 2012, BMJ : British Medical Journal.

[58]  K. Kahn,et al.  The Role of Primary Care Physicians in Cancer Care , 2009, Journal of General Internal Medicine.

[59]  A. Bischoff,et al.  Uptake of breast cancer screening measures among immigrant and Swiss women in Switzerland. , 2008, Swiss medical weekly.

[60]  Richard L. Street,et al.  Patient-centered communication in cancer care: Promoting healing and reducing suffering , 2007 .

[61]  P. Butow,et al.  www.mja.com.au Supplement , 2007 .